Compare Abbott Laboratories (ABT) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs JPMorgan Chase & Co — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while JPMorgan Chase & Co trades at $332.9 (market cap $908.94B). The key difference: JPMorgan Chase & Co is far larger — about 5.4× Abbott Laboratories's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | JPM | |
|---|---|---|
Market Cap | $166.94B | $908.94B |
Sector | Health | Financials |
52-Week High | $136.62 | $339.22 |
52-Week Low | $82.57 | $282.78 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 1.77% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
JPMorgan Chase (JPM) trades at $333.43, down 1.27% over the past day, with a P/E of 16.24 and P/B of 2.64. Recent earnings show mixed results, beating expectations in Q1 2026 but missing in Q4 2025. The stock exhibits a bullish technical trend, supported by strong moving averages and a consensus analyst price target of $360.38. Revenue grew to $181.85B in 2025, though net income dipped slightly to $57.05B. Institutional sentiment remains positive, with 51.67% of analysts rating it a Buy.
Outlook: JPMorgan's robust ROE of 17.03% and steady revenue growth support a favorable long-term view, but risks include geopolitical tensions, cybersecurity threats, and volatile cash flows. The stock presents a solid opportunity for value investors, though macroeconomic headwinds and interest rate sensitivity warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
